Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fluorescent Probe for Assessment of Renal Elimination (FLARE)

31. august 2026 oppdatert av: Aaron Cook
Accurate measures of kidney function is important for precision dosing of many medications. The current methods of determining kidney function largely hinge on the use of equations that use common laboratory values such as serum creatinine & static variables like age & weight. These are helpful for trending over time, but often are inaccurate during times of medical illness. Other more accurate methods of measuring kidney function include urine collection, although this is not commonly used because of various reasons that make the collection inconvenient or unreliable. The new transdermal glomerular filtration (tGFR) device permits accurate, real-time evaluation of kidney function. This novel method has not been rigorously compared with urine collection & other methods of determining kidney function in hospitalized patients. The goal of the study is to compare tGFR with other accepted methods of determining kidney function.

Studieoversikt

Detaljert beskrivelse

The majority of acutely ill patients exhibit changes in renal function due to inflammation, increased solute generation, and iatrogenic factors such as fluid resuscitation and vasopressors. The pharmacokinetics of renally eliminated medications (eg. levetiracetam, cefepime, vancomycin) are frequently affected by inflammatory processes despite normal estimations in creatinine clearance resulting in suboptimal serum drug concentrations and therapeutic failure. Despite the prevalence of fluctuations in renal function in acute illness, real-time assessment is limited to monitoring of serum biomarkers such as creatinine and cystatin C, as well as urine output, which typically lag behind important changes in function. Furthermore, use of creatinine clearance equations based on anthropomorphic data correlates poorly with actual renal function, potentially misleading clinicians as to the progression of disease and the need for dose adjustment of important medications in this vulnerable population.

Limitations of current approaches for evaluating renal function in the acutely ill Estimation of GFR or creatinine clearance can be accomplished by numerous equations, the majority of which have been validated in non-critically ill adults, usually with a relatively high percent of patients with chronic kidney disease. These equations are often not accurate in patients with acutely worsening renal function. Likewise, while these equations are helpful for categorizing renal function and assessing appropriate medication dosing in otherwise healthy, ambulatory patients. Under-prediction of creatinine clearance values leads clinicians to consistently under-dose critical medications such as beta-lactam antibiotics, vancomycin, or antiseizure medications such as levetiracetam.

Proactive measurement of creatinine clearance can provide a more accurate depiction of GFR but is fraught with complications. Iohexol serum concentrations correlate well with GFR, but requires intravenous administration of iohexol, which has a small risk of infusion reaction and hypersensitivity, and serial blood samples. Measured urine creatinine clearance is also feasible but inconvenient in most hospitalized patients. mClCr requires bladder catheterization for accurate urine volume, consistent storage on ice for the duration of collection (between 8 and 24 hours), and prompt delivery of the large volume container to the local laboratory for creatinine analysis. Each of these criteria introduce variability into the measurement and are often unnoticed or undocumented, introducing inaccuracy into the mClCr values. The lack of a real-time, accurate assessment of creatinine clearance in the acutely ill population is a gap in practice and represents a resolvable problem in the process of individualized and precision dosing of medications in this vulnerable and high-risk population.

This study represents an important innovation in advancing the understanding of fluctuations in renal function during acute illness. The current study will validate the safety of transdermal GFR monitoring to provide real-time measurement of renal function in patients with stable renal function. Further, the reliability of transdermal GFR monitoring will be compared to current standards of renal function assessment. The results of this study will advance the field by validating the use of a real-time physiologic assessment of GFR rather than using labor intensive, invasive tests that may lag behind current renal function. Numerous important gaps remain with this new technology, including use primarily in the ambulatory, stable renal function populations. Thus, this study is potentially the first step in evaluating renal function across the acute care continuum.

Studietype

Intervensjonell

Registrering (Antatt)

200

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Aaron Cook, PharmD
  • Telefonnummer: 18592578444
  • E-post: amcook0@uky.edu

Studiesteder

    • Kentucky
      • Lexington, Kentucky, Forente stater, 40536
        • UKHealthCare/University of Kentucky

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • 18-65 years old
  • critically ill or acutely ill hospitalized patients admitted to the intensive care unit
  • Stable/normal renal function

Exclusion Criteria:

  • Prisoners
  • Pregnant women
  • Laboratory evidence of unstable kidney function (KDIGO AKI stage 1-3--This includes subjects with Scr > 1.5x baseline)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: MediBeacon Transdermal Glomerular Filtration Rate (GFR) Monitoring
IV push of relmapirazin (Lumitrace) prior to use of the tGFR device
Small IV push bolus of iohexol as a probe for renal function will be administered prior to use of the tGFR device.
The tGFR monitor will be applied to the patient after relmapirazin bolus for measurement of GFR.
8-hour urine creatinine clearance collection will be performed during the study period to compare to tGFR & other renal function measures.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Transdermal Glomerular Filtration Rate (tGFR) Monitoring Accuracy
Tidsramme: 8 Hours
Accuracy of transdermal glomerular filtration rate (GFR) monitoring compared with measured urine creatinine clearance.
8 Hours

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Relmapirazin Elimination Half-Life
Tidsramme: 12 hours
Elimination half-life of Relmapirazin calculated from serial serum concentration measurements obtained over 12 hours following intravenous administration.
12 hours
Iohexol Elimination Half-Life
Tidsramme: 12 hours
Elimination half-life of Iohexol calculated from serial serum concentration measurements obtained over 12 hours following intravenous administration.
12 hours

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Aaron M Cook, PharmD, University of Kentucky College of Pharmacy, Department of Pharmacy Practice & Science
  • Studieleder: Juan-Carlos Aycinena, MD, University of Kentucky College of Medicine, Department of Nephrology

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. september 2026

Primær fullføring (Antatt)

31. mai 2028

Studiet fullført (Antatt)

30. juni 2028

Datoer for studieregistrering

Først innsendt

8. mai 2026

Først innsendt som oppfylte QC-kriteriene

8. juni 2026

Først lagt ut (Faktiske)

11. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

31. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere